Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K J Bulpitt

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Journal of Rheumatology|May 17, 2000
Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing RheumatologistsK Newhall-Perry, N J Law, B Ramos, et al.
The New England Journal of Medicine|January 28, 1999
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateM E Weinblatt, J M Kremer, A D Bankhurst, et al.
British Journal of Rheumatology|March 1, 1996
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging studyJ D Isaacs, V K Manna, N Rapson, et al.
Arthritis and Rheumatism|November 1, 1995
CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation studyM E Weinblatt, P J Maddison, K J Bulpitt, et al.
Arthritis and Rheumatism|December 2, 2006
Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practiceK L Kahn, C H MacLean, H Liu, et al.
Annals of Internal Medicine|April 15, 1993
Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis)K J Bulpitt, P J Clements, P A Lachenbruch, et al.
Annals of Internal Medicine|March 13, 1999
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trialL W Moreland, M H Schiff, S W Baumgartner, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Journal of Rheumatology|May 17, 2000
Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing RheumatologistsK Newhall-Perry, N J Law, B Ramos, et al.
The New England Journal of Medicine|January 28, 1999
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateM E Weinblatt, J M Kremer, A D Bankhurst, et al.
British Journal of Rheumatology|March 1, 1996
CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging studyJ D Isaacs, V K Manna, N Rapson, et al.
Arthritis and Rheumatism|November 1, 1995
CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation studyM E Weinblatt, P J Maddison, K J Bulpitt, et al.
Arthritis and Rheumatism|December 2, 2006
Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practiceK L Kahn, C H MacLean, H Liu, et al.
Annals of Internal Medicine|April 15, 1993
Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis)K J Bulpitt, P J Clements, P A Lachenbruch, et al.
Annals of Internal Medicine|March 13, 1999
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trialL W Moreland, M H Schiff, S W Baumgartner, et al.
Pageof 2